Ribobio Submits Phase I Clinical Trial Application for siRNA Drug RBD3133 Targeting INHBE to EU

Ribobio Biotechnology Limited (06938.HK) and its subsidiary, Ribocure Pharmaceuticals AB, have successfully submitted an Investigational New Drug (IND) application for their self-developed small nucleic acid drug, RBD3133, to the European Union. RBD3133 is an innovative siRNA candidate drug targeting INHBE (Inhibin Subunit Beta E), intended for the treatment of overweight and obesity. The submission of the Phase I clinical trial application for RBD3133 marks a significant milestone for Ribobio in advancing its pipeline of therapeutic candidates. By focusing on targeting INHBE, the company aims to address the medical needs of individuals struggling with weight-related conditions. Ribobio’s decision to pursue clinical…